ライフサイエンスコーパス: COPD exacerbation

1 s with persistent hypercapnia after an acute COPD exacerbation.

2 sthma exacerbation and 131,974 patients with COPD exacerbation.

3 ts with asthma exacerbation and 162,899 with COPD exacerbation.

4 was the time to the first moderate or severe COPD exacerbation.

5 h increased respiratory symptoms and risk of COPD exacerbation.

6 on symptom, is useful in the confirmation of COPD exacerbation.

7 rticosteroids in the outpatient treatment of COPD exacerbations.

8 e primary outcome was the annual rate of all COPD exacerbations.

9 g NIV failure (25-15%) in severe hypercapnic COPD exacerbations.

10 hree dihexosylceramides were associated with COPD exacerbations.

11 a and glycosphingolipids are associated with COPD exacerbations.

12 d with a clinically significant reduction in COPD exacerbations.

13 ses in nocturnal symptoms and risk of severe COPD exacerbations.

14 f teeth and thus may reduce the frequency of COPD exacerbations.

15 s, rescue medication use, and risk of severe COPD exacerbations.

16 h increased respiratory symptoms and risk of COPD exacerbations.

17 ry tract contributes to approximately 50% of COPD exacerbations.

18 atio] of >1) would be associated with severe COPD exacerbations.

19 ondary bacterial infections in virus-induced COPD exacerbations.

20 as important cellular targets in controlling COPD exacerbations.

21 ve drugs for the prevention and treatment of COPD exacerbations.

22 inophilic airway inflammation contributes to COPD exacerbations.

23 acute chronic obstructive pulmonary disease (COPD) exacerbation.

24 er of chronic obstructive pulmonary disease (COPD) exacerbations.

25 9 (2.1-38), 23 (8.8-58), and 36 (12-105) for COPD exacerbations; 1.5 (0.9-2.2), 1.6 (1.0-2.4), and 2.

26 ropium patients were hospitalized because of COPD exacerbation (7.0% vs. 9.5%, respectively; differen

27 predictive value [NPV]; treatment efficacy (COPD exacerbations, all-cause mortality, quality of life

28 with chronic obstructive pulmonary disease (COPD) exacerbations among individuals with COPD in the g

29 oints were the percentage of patients with a COPD exacerbation and the percentage of patients with a

30 roup performed telephone-based assessment of COPD exacerbations and hospitalizations, and all hospita

31 tibiotic treatment has been shown to prevent COPD exacerbations and hospitalizations.

32 Tiotropium reduces COPD exacerbations and may reduce related health care ut

33 Blood fibrocytes are recruited during COPD exacerbations and related to mortality and low lung

34 d reduce the incidence of moderate or severe COPD exacerbations and upper respiratory infections.

35 uring chronic obstructive pulmonary disease (COPD) exacerbations and is a plausible target for MAIT c

36 h asthma had an increased risk of asthma and COPD exacerbations, and possibly pneumonias.

37 COPD exacerbations are associated with increased airway

38 COPD exacerbations are most often associated with viral

39 Chronic obstructive pulmonary disease (COPD) exacerbations are associated with virus (mostly rh

40 ents did not cause a significant increase in COPD exacerbations, but did reduce total systemic cortic

41 rker to direct corticosteroid therapy during COPD exacerbations, but larger studies are required.

42 as superior in preventing moderate to severe COPD exacerbations compared with the single longacting a

43 Chronic obstructive pulmonary disease (COPD) exacerbations contribute significantly to morbidit

44 lycopyrronium for rate of moderate to severe COPD exacerbations (defined by worsening symptoms and ca

45 he percentages of individuals experiencing a COPD exacerbation during the first year of observation w

46 ing the first 2 hrs of treatment of an acute COPD exacerbation failed to improve FEV1 faster than the

47 COPD exacerbation frequency was related to stable-state

48 ng emphysema percentage were associated with COPD exacerbation frequency.

49 with respect to the first moderate or severe COPD exacerbation (hazard ratio, 1.06; 95% CI, 0.94 to 1

50 n the reduction of hospital readmissions for COPD exacerbations, health systems in the USA struggle t

51 ) for chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the

52 for an average period of 4.3 years regarding COPD exacerbations, hospital admissions, and mortality.

53 COPD exacerbations impair quality of life and are charac

54 nt of chronic obstructive pulmonary disease (COPD) exacerbations improves outcomes; however, response

55 ease stages III-IV, and one or more moderate COPD exacerbation in the past year) were randomly assign

56 ss than 50%, at least one moderate-to-severe COPD exacerbation in the previous 12 months, and a COPD

57 wer than 50%, one or more moderate-to-severe COPD exacerbation in the previous 12 months, COPD Assess

58 The frequency of COPD exacerbation in the prior year was determined by us

59 lung microenvironment on rhinovirus-induced COPD exacerbation in vivo.

60 oviruses) were detected in 66 (39.2%) of 168 COPD exacerbations in 53 (64%) patients.

61 chment biomarker for all-cause mortality and COPD exacerbations in July 2015.

62 ve than salmeterol-fluticasone in preventing COPD exacerbations in patients with a history of exacerb

63 approach for the treatment and prevention of COPD exacerbations in the future.

64 ment Test [CAT] >/=10 vs <10) in addition to COPD exacerbations in the previous year (<2 vs >/= 2), a

65 d airway wall thickness were associated with COPD exacerbations, independent of the severity of airfl

66 ded blood eosinophils at baseline and future COPD exacerbations longitudinally, defined as moderate (

67 n in COPD and is associated with more severe COPD exacerbations, lower airway bacterial colonization,

68 pt that bacteria infecting the airway during COPD exacerbations mediate increased airway inflammation

69 inophil count is associated with the risk of COPD exacerbations, mortality, decline in FEV1, and resp

70 uenzae strains isolated from patients during COPD exacerbations often induce more airway inflammation

71 ADRB2 polymorphisms differentially affected COPD exacerbation outcomes in response to tiotropium ver

72 at tiotropium may lengthen the time to first COPD exacerbation (P = 0.028) and reduce health care uti

73 018), but no evidence of an association with COPD exacerbations (p=0.35) or the other indices of COPD

74 is common and clinically significant during COPD exacerbations, particularly in those with underlyin

75 Arterial stiffness rises acutely during COPD exacerbations, particularly with airway infection.

76 nting to the emergency department with acute COPD exacerbation, past or present smokers (>/=20 pack-y

77 The number of COPD exacerbations per patient (primary outcome) was 2.5

78 ma or chronic obstructive pulmonary disease (COPD) exacerbations, pneumonias, lung cancer, ischemic h

79 tware, could estimate joint heterogeneity in COPD exacerbation rate and severity and can have applica

80 ondary endpoints included moderate-to-severe COPD exacerbation rate over 52 weeks.

81 The primary endpoint was moderate-to-severe COPD exacerbation rate.

82 ns (rate ratio, 1.01; 95% CI, 0.91 to 1.13), COPD exacerbations (rate ratio, 1.08; 95% CI, 0.98 to 1.

83 United States seem to be at greater risk for COPD exacerbation-related mortality than those living in

84 .5; P < 0.05), and to have increased risk of COPD exacerbation requiring an acute doctor visit (OR, 1

85 m Short-Form Physical Component (SF-12), and COPD exacerbations requiring health care utilization, ad

86 ough (OR, 4.20; P = 0.03), increased risk of COPD exacerbations requiring treatment with antibiotics

87 The most common serious adverse events were COPD exacerbation resulting in admission to hospital (ei

88 ed Trial of Simvastatin in the Prevention of COPD Exacerbations (STATCOPE) as a randomized, controlle

89 l Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily lon

90 ug vs. HandiHaler) and the risk of the first COPD exacerbation (superiority study, Respimat at a dose

91 uticasone in reducing the annual rate of all COPD exacerbations; the rate was 11% lower in the indaca

92 of the use of azithromycin for prevention of COPD exacerbations (United States and Canada, 2006-2010;

93 COPD exacerbation was the most common serious adverse ev

94 An experimental human model of COPD exacerbation was used to investigate the levels of

95 versus salmeterol-fluticasone on the rate of COPD exacerbations was independent of the baseline blood

96 A total of 215 patients hospitalized for a COPD exacerbation were randomized at hospital discharge

97 Twenty-seven patients presenting with acute COPD exacerbation were studied.

98 Subjects with COPD exacerbations were entered into a randomized biomar

99 , 0.03-8.1), 1,439 severe and 2,864 moderate COPD exacerbations were recorded.

100 se of chronic obstructive pulmonary disease (COPD) exacerbation were examined by monitoring changes i

101 In subjects with COPD, exacerbations were associated with excess FEV1 dec

102 and reduced inflammation in a model of viral COPD exacerbation, which do not affect viral clearance.

103 re are no biomarkers to objectively diagnose COPD exacerbations, which are the major drivers of hospi

104 n rates after an index hospitalization for a COPD exacerbation will be penalized with reduced reimbur

105 Outpatient treatment of acute COPD exacerbation with prednisone accelerates recovery o

106 Inclusion criteria were COPD exacerbations with PaCO2 >/= 45 mm Hg, pH </= 7.35,